Sector News

Horizon is world leader in gene-editing with Sage buy

October 1, 2014
Life sciences
The UK’s Horizon Discovery is acquiring Sage Labs of the USA in a deal which it says will create “the world’s leading gene-editing and translational genomics company”.
 
The Cambridge-headquarted group is paying up to $48 million ($16 million in cash and $32 million in new shares) for Sage, described as “a world leader in the generation of advanced in vivo transgenic disease models for use in preclinical research”. It builds upon the $8 million acquisition of CombinatoRx in July and Horizon says it is now the “go-to company for the provision of integrated product, service and research solutions at all stages of translational genomics and personalised medicine research from sequence to treatment”.
 
Sage belonged to Sigma-Aldrich before a buy-out in 2013 and has 50 employees, a direct US and European sales force and 43,000 square feet state-of-the-art facilities. This will enable the scale-up of Horizon’s product and service offerings “through access to new capabilities, capacity and access to new markets”.
 
David Smoller, Sage chief executive who will now become Horizon’s chief business officer, said the new firm “is now the destination for researchers and scientists worldwide to find both in vivo and in vitro solutions to their biological questions”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach